HOME > BUSINESS
BUSINESS
- BMKK Applies for Orencia SC Injection
July 11, 2012
- Takeda to Offer US Dollar Senior Notes for Repaying Debt for Nycomed Acquisition
July 11, 2012
- Taisho HD Acquires Mexican Pharmaceutical Companies to Enter OTC Drug Business
July 11, 2012
- Shionogi Launches First European Development Base
July 10, 2012
- Otsuka Licenses Digital Health Technology from Proteus of the US
July 10, 2012
- Astellas Launches RLS Treatment Regnite on July 10
July 10, 2012
- Pharmaceutical Companies Set Up Private Power Generators in Preparation for Planned Power Outages
July 9, 2012
- Ethical Drug Sales Up 9.7% in May, Pushed by 2 Extra Working Days: Crecon Report
July 9, 2012
- MTPC Launches Argatroban for HIT Type II in the UK
July 9, 2012
- Bayer Confident in Pipeline, Regards Japan as Strategically Important Country: Mr Fibig
July 6, 2012
- Takeda Completes Acquisition of Multilab, Mid-Sized Brazilian Pharm Company
July 5, 2012
- Zonegran Approved for Monotherapy in Europe: Eisai
July 5, 2012
- Nippon Kayaku Considers Promotional Measures for Biosimilars, Vascular Embolization Medical Devices
July 5, 2012
- AZ to Promote Symbicort, SMART Therapy Targeting GPs, Specialists
July 5, 2012
- Ono to Start PI Trial for Anticancer Vaccine Licensed from OncoTherapy
July 5, 2012
- Japan Becomes World No. 2 Vaccine Market Pushed by HPV Vaccines
July 4, 2012
- Sanofi, Hisamitsu Set Up Joint Venture with Sanofi Chief as President and Chairman
July 4, 2012
- AnGes MG to License Exclusive US Marketing Rights for Collategene to MTPC
July 4, 2012
- 230 MSs of Mediceo Begin to Work as ARs for Sawai
July 4, 2012
- COPD Treatment Oxis Approved, to Be Marketed by Meiji Seika Pharma: AZ
July 4, 2012
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…